Advertisement

The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo

  • Author Footnotes
    1 These authors contributed equally to this work.
    Aviad Keren
    Footnotes
    1 These authors contributed equally to this work.
    Affiliations
    Skin Research Laboratory, Faculty of Medicine, Technion – Israel Institute of Technology, Flieman Medical Center, PO Box 9649, Haifa, Israel
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
    Avner Shemer
    Footnotes
    1 These authors contributed equally to this work.
    Affiliations
    Skin Research Laboratory, Faculty of Medicine, Technion – Israel Institute of Technology, Flieman Medical Center, PO Box 9649, Haifa, Israel
    Search for articles by this author
  • Yehuda Ullmann
    Affiliations
    Skin Research Laboratory, Faculty of Medicine, Technion – Israel Institute of Technology, Flieman Medical Center, PO Box 9649, Haifa, Israel
    Search for articles by this author
  • Ralf Paus
    Affiliations
    Centre for Dermatology Research, Inst. of Inflammation and Repair, University of Manchester, Manchester, UK

    Department of Dermatology, University of Münster, Münster, Germany
    Search for articles by this author
  • Amos Gilhar
    Correspondence
    Corresponding author at: Technion – Israel Institute of Technology, PO Box 9649, Bat-Galim, Haifa 31096, Israel. Tel.: +972 48307092.
    Affiliations
    Skin Research Laboratory, Faculty of Medicine, Technion – Israel Institute of Technology, Flieman Medical Center, PO Box 9649, Haifa, Israel
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work.
Published:December 03, 2014DOI:https://doi.org/10.1016/j.jdermsci.2014.11.009

      Highlights

      • Alopecia areata (AA) is an autoimmune disease.
      • The disease is mediated by cooperation between CD8+/NKG2D+ CD4+ cells.
      • Genes coding for NKG2D ligands such as MICA and ULBP3 are associated with AA.
      • Transfer of activated PBMCs into human scalp skin/SCID mice induces AA-feature.
      • Apremilast targets PDE4, suppresses AA in the humanized scalp skin/SCID mouse model.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Dermatological Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gilhar A.
        • Keren A.
        • Shemer A.
        • Ullmann Y.
        • Paus R.
        Blocking potassium channels (Kv1.3): a new treatment option for alopecia areata?.
        J Invest Dermatol. 2013; 133: 2088-2091
        • Gilhar A.
        • Keren A.
        • Shemer A.
        • d’Ovidio R.
        • Ullmann Y.
        • Paus R.
        Autoimmune disease induction in a healthy human organ: a humanized mouse model of alopecia areata.
        J Invest Dermatol. 2013; 133: 844-847
        • Bertolini M.
        • Zilio F.
        • Rossi A.
        • Kleditzsch P.
        • Emelianov V.E.
        • Gilhar A.
        • et al.
        Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata.
        PLOS ONE. 2014; 9: e94260
        • Gilhar A.
        • Etzioni A.
        • Paus R.
        Alopecia areata.
        N Engl J Med. 2012; 366: 1515-1525
        • Petukhova L.
        • Duvic M.
        • Hordinsky M.
        • Norris D.
        • Price V.
        • Shimomura Y.
        • et al.
        Genome-wide association study in alopecia areata implicates both innate and adaptive immunity.
        Nature. 2010; 466: 113-117
        • Schafer P.H.
        • Day R.M.
        Novel systemic drugs for psoriasis: mechanism of action for apremilast, a specific inhibitor of PDE4.
        J Am Acad Dermatol. 2013; 68: 1041-1042
        • Poole R.M.
        • Ballantyne A.D.
        Apremilast: first global approval.
        Drugs. 2014; 74: 825-837
        • Ito T.
        • Ito N.
        • Bettermann A.
        • Tokura Y.
        • Takigawa M.
        • Paus R.
        Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model.
        Am J Pathol. 2004; 164: 623-634